Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07490041 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Name: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases — clinical trial record (NCT07490041)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Cell therapy

StatusRecruiting

PhaseEarly Phase 1

SponsorThe Children's Hospital of Zhejiang University School of Medicine

Started2026-03-19

View on ClinicalTrials.gov ↗

The Children's Hospital of Zhejiang University School of Medicine

58 trials monitored

See all monitored trials

Lupus (SLE)

648 trials monitored

See 25 trials at risk

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.

Trial Details

NCT Number	NCT07490041
Lead Sponsor	The Children's Hospital of Zhejiang University School of Medicine Collaborators: Rui Therapeutics Co., Ltd
Conditions	Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE), Connective Tissue Disease-associated Interstitial Lung Disease
Enrollment	36 participants
Start Date	2026-03-19
Primary Completion	2026-12-19 (estimated)
Study Completion	2027-12-19 (estimated)
Updated on ClinicalTrials.gov	2026-03-24